Endovia Health Sciences sets interim CEO, COO pay at $300,000 and $275,000 with market-cap bonuses up to $300,000
PUBT · 2d ago
Share
Listen to the news
- Endovia Health Sciences entered employment agreements on Aug. 20, 2026 with interim CEO Brady Cobb, interim COO Michael Bondurant.
- Cobb base salary set at USD 300,000; Bondurant at USD 275,000.
- Each can earn USD 50,000 if market cap rises USD 5 million by Oct. 30, 2026; another USD 50,000 if USD 10 million by Dec. 31.
- Additional bonus set at 3% of market-cap gains above the USD 10 million threshold in 2026, capped at USD 300,000.
- Cobb received 231,250 options; Bondurant received 200,000; shareholder-approved RSUs tied to 7% of a 20% fully diluted share pool.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endovia Health Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001152), on August 26, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending